Car-T patient story

In 2017, Kelly Lamphere accepted CAR-T treatment when she was 47. It wasn’t sure how much time she had left. In August 2017

January 13, 2020

Lamphere received a phone call that changed everything. It's about a spot opened on a clinical trial(CAR-T). She took it, traveling to Boston with her husband. The treatment

Know More

A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma

December 19, 2019

Chimeric antigen receptor (CAR) T cell therapy has demonstrated proven efficacy in some hematologic cancers. We evaluated the safety and efficacy of LCAR-B38M

Know More

in patients with relapsed/refractory multiple myeloma

Aug 9, 2019

Phase I results of the LEGEND-2 trial: LCAR-B38M CAR-T therapy for patients with relapsed or refractory multiple myeloma,LCAR-B38M is a chimeric antigen receptor T-cell (CAR T-cell) therapy that dually binds two distinct B cell maturation antigen (BCMA) epitopes

Know More

Autologous BCMA-CART successfully treats refractory relapsed multiple myeloma with TP53 gene mutation

Aug 02, 2019

Autologous BCMA-CART successfully treats refractory relapsed multiple myeloma with TP53 gene mutation and central nervous system infiltration

Know More

Mr. Chase stayed in the hospital again to receive CAR-T cell r

Aug 02, 2019

Mr. Chase stayed in the hospital again to receive CAR-T cell reinfusion treatment Let the patient get a new life

Know More

the earlier you start your treatment, the higher your chances to achieve Complete Remission (CR)

apply